StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report issued on Tuesday. The brokerage issued a sell rating on the stock.

Other equities analysts have also recently issued reports about the company. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, HC Wainwright restated a “neutral” rating and issued a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, Syros Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Stock Up 0.1 %

SYRS opened at $0.23 on Tuesday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. The company has a market capitalization of $6.17 million, a PE ratio of -0.08 and a beta of 1.34. The stock’s fifty day moving average is $0.83 and its 200-day moving average is $2.57. Syros Pharmaceuticals has a one year low of $0.18 and a one year high of $7.98.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter last year, the company earned ($1.35) earnings per share. On average, equities analysts predict that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Nancy A. Simonian sold 134,713 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the sale, the director now directly owns 41,070 shares in the company, valued at approximately $11,088.90. This trade represents a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.26% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals during the 3rd quarter valued at about $34,000. Acadian Asset Management LLC raised its position in Syros Pharmaceuticals by 101.5% during the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after acquiring an additional 17,416 shares in the last quarter. Certuity LLC bought a new stake in Syros Pharmaceuticals in the second quarter worth approximately $109,000. Finally, Exome Asset Management LLC increased its stake in shares of Syros Pharmaceuticals by 87.6% during the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after purchasing an additional 139,400 shares during the last quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.